ReviewOncology and therapy2017
Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review.
Review in Oncology and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Eligibility versus appropriateness in allogeneic HCT.Blood advances · 2026Article
- Nutrition and Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults (Aged ≥60): A Scoping Review.Journal of the Academy of Nutrition and Dietetics · 2025Article
- Research priorities to address supportive care needs in acute myeloid leukaemia (AML)-results from a Delphi survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Fatigue in hematological cancer changes across chemotherapy trajectory within the context of IL-6, not hemoglobin level: evidence from growth curve modeling.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- CXCR4-directed endoradiotherapy with [Theranostics · 2025Article
- Trajectories of physical well-being among adults with acute myeloid leukemia.Blood advances · 2024Article
- Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors.BMJ supportive & palliative care · 2023Article
- Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.Journal of personalized medicine · 2023Article
- Health-Related Quality of Life and Treatment Satisfaction of Patients with Blood Cancer in Kazakhstan: A Cross-Sectional Study.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Research Strategy for the Development of a Quality-of-Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia.Journal of the advanced practitioner in oncology · 2023Article
- Determinants of quality of life of cancer patients at a tertiary care medical city in Riyadh, Saudi Arabia.Frontiers in psychiatry · 2023Article
- Article
- Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.Blood cancer journal · 2022Article
- It doesn't stop at validation: patient reported outcome measures require ongoing and iterative development.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling.Psycho-oncology · 2021Article
- Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.American journal of blood research · 2021Review
- Characterising experiences with acute myeloid leukaemia using an Instagram content analysis.PloS one · 2021Article
- Oral Health-Related Quality of Life in Adult Patients with Newly Diagnosed Acute Leukaemia.Oral health & preventive dentistry · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with acute myeloid leukemia (AML), especially those with relapsed or refractory AML, have poor clinical prognosis and outcomes. Health-related quality of life (HRQoL) assessments have become increasingly important in oncology, aiding in identifying and informing supportive therapy needs during treatment and beyond; however, HRQoL in hematology, and AML in particular, has received relatively minor attention. The aim was to identify and summarize estimates of HRQoL in patients with AML, including patients with relapsed or refractory AML.
methodsA systematic literature review was performed. MEDLINE and EMBASE databases were searched for peer-reviewed literature published between 2004 and 2014 in the US and Europe. Abstracts from four relevant conference proceedings between 2012 and 2014 were reviewed. Data from eligible studies were extracted describing the HRQoL instruments used, domains assessed, and HRQoL scores reported.
resultsFourteen peer-reviewed studies met the eligibility criteria and were included in the review. Cancer- or leukemia-specific HRQoL measures were used in 78.6% of the studies. Overall, HRQoL was superior among AML survivors compared to individuals on active treatment. Fatigue was identified as the most problematic symptom domain in patients, irrespective of their treatment status. Reported HRQoL declined shortly after diagnosis or treatment initiation and recovered over time.
conclusionThe included studies identified a decrease in HRQoL after treatment initiation and highlighted the role of fatigue in HRQoL in this patient population. Limited HRQoL data were identified among relapsed or refractory AML patients although they have worse prognostic outcomes. New treatment options that have less negative impact on HRQoL or health initiatives specifically targeting HRQoL of patients with AML are warranted. In addition, further studies exploring HRQoL in the relapsed or refractory patient population are needed to inform disease management and treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.